US Regulatory Roundup – September 2022: Philips Troubles, Software And User Fees
Executive Summary
The ten most popular stories about US regulatory issues published by Medtech Insight last month were a mixed bag, with a Philips recall taking the top spot and stories about AI, user fees, and more adding to the list.
You may also be interested in...
US Interim Funding Bill Gets President Biden’s Signature; Window Narrows For IVD Reg Reform
Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs including MDUFA. Policy riders stripped from the legislation, including for FDA oversight of lab-developed tests, could still find their way into a final FY 2023 spending omnibus.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.